| Type | Title | Date Released | |
|---|---|---|---|
8-K | Pulse Biosciences Presents Positive Six-Month Interim Results from PRECISE-BTN Study of nPulse Vybrance System for Benign Thyroid Nodules | ||
10-Q | Form 10-Q | ||
8-K | Pulse Biosciences Reports Third Quarter 2026 Financial Results and Business Updates | ||
8-K | Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center for nPulse Vybrance System | ||
8-K | Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study for nPulse Cardiac Catheter System | ||
8-K | Pulse Biosciences Enters into $85 Million Equity Distribution Agreement with Mizuho and Terminates TD Cowen Agreement | ||
424B5 | [No Baby Shelf]* September 2026 ATM | Offering amount: $85,000,000 | Bank: Mizuho Securities USA LLC | ||
8-K | Pulse Biosciences Completes 100-Patient Enrollment in PRECISE-BTN Clinical Study for Benign Thyroid Nodules | ||
4 | Teplitsky Liane Rae (Reporting) | ||
4 | Teplitsky Liane Rae (Reporting) | ||
4 | Teplitsky Liane Rae (Reporting) | ||
3 | Teplitsky Liane Rae (Reporting) |